News
-
-
-
PRESS RELEASE
Sanofi: Disclosure of trading in own shares
-
-
PRESS RELEASE
Press Release: ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s disease
Sanofi and Teva Pharmaceuticals present new detailed data from the RELIEVE UCCD study on duvakitug's efficacy in ulcerative colitis and Crohn's disease at ECCO 2025, demonstrating potential for phase 3 program in H2 2025 -
-
-
-
-
PRESS RELEASE
Sanofi: Disclosure of trading in own shares